当前位置: 首页 > 期刊 > 《中国现代医生》 > 2011年第36期 > 正文
编号:12144128
阿托伐他汀联合吡格列酮对大鼠缺血再灌注心肌的保护作用(1)
http://www.100md.com 2011年12月25日 祖玉刚 陈还珍
第1页

    参见附件(1990KB,2页)。

     [摘要] 目的 探讨阿托伐他汀、吡格列酮及二者联用预处理大鼠后,对缺血再灌注(I/R)心肌的保护作用,并探讨其可能的机制。方法 选雄性健康Sprague-Dawley(SD)大鼠40只,将上述大鼠随机分为5组:假手术组(生理盐水,2mL/d,8例)、I/R组(生理盐水,2mL/d,8例)、阿托伐他汀组[阿托伐他汀,20mg/(kg·d),8例]、吡格列酮组[吡格列酮,3mg/(kg·d),8例]、阿托伐他汀+吡格列酮组[阿托伐他汀,20mg/(kg·d)+吡格列酮3mg/(kg·d),8例]。灌胃1周后,第8天制作大鼠在体心肌I/R模型。缺血30min,再灌注1h后测定血清丙二醛(MDA)及超氧化物歧化酶(SOD);Evans blue、TTC双重染色后,用图像分析软件计算梗死面积。结果 阿托伐他汀组、吡格列酮组、阿托伐他汀+吡格列酮组与I/R组比较,心肌梗死面积减少,SOD升高、MDA降低(P<0.01)。联合用药组较单独用药组心肌梗死面积减少,SOD升高,MDA降低(P<0.01);较假手术组SOD降低,MDA升高(P<0.01)。阿托伐他汀组与吡格列酮组各指标水平接近(P>0.05)。 结论 阿托伐他汀、吡格列酮能减轻心肌缺血再灌注损伤,两药联合应用作用更加明显,其作用机制与提高血清SOD活性,降低MDA含量有关。

    [关键词] 冠心病;阿托伐他汀;吡格列酮;心肌缺血再灌注;保护作用

    [中图分类号] R965 [文献标识码] A [文章编号] 1673-9701(2011)36-04-02

    Protective Effect of Atorvastatin and Pioglitazone on Ischemia and Reperfusion Myocardium in Rats

    ZU Yugang CHEN Huanzhen

    Department of Cardiology,the First Hospital of Shanxi Medical University, Taiyuan 030001,China

    [Abstract] Objective To investigate atorvastatin,pioglitazone and two drugs in combination on ischemia-reperfusion myocardial protective effects and the possible mechanism. Methods All 40 healthy SD rats were randomly divided into 5 groups:sham operation group(n=8,0.9%sodium chloride injection liquid,2mL/d),I/R group(n=8,0.9% sodium chloride injection liquid,2mL/d),atorvastatin group[(n=8,atorvastatin,20mg/kg·d)],pioglitazone group[n=8,pioglitazone 3mg/(kg·d)],atorvastatin + pioglitazone group[n=8,atorvastat in,20mg/(kg·d)+pioglitazone 3mg/(kg·d)].After one week gavage make the rat model of myocardial ischemia-reperfusion in eight days,ischemia 30minute,one hour after reperfusion serum malondialdehyde(MDA) and superoxide dismutase(SOD).Evans blue,TTC double staining,using image analysis software to calculate infarct size. Results The atorvastatin group,pioglitazone group,atorvastatin + pioglitazone group and I/R group,infarct size reduction,SOD increased,MDA decreased(P<0.01).Atorvastatin + pioglitazone group than in the atorvastatin group,pioglitazone group myocardial infarct size reduction,SOD increased ......

您现在查看是摘要介绍页,详见PDF附件(1990KB,2页)